Physician profile
Kristi Eilers
NPI 1083196349
$1,807.62
in general payments reported to CMS, 2019-2025
15 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $126 · 2023: $279 · 2024: $408 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.43 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $617.62 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $581.74 | 2022-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $123.27 | 2025 | Cobenfy |
| Alkermes, INC. | $73.44 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.07 | 2021 | |
| Sunovion Pharmaceuticals INC. | $59.51 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $57.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $57.26 | 2021 | |
| Neurocrine Biosciences, INC. | $42.71 | 2022 | |
| Axsome Therapeutics, INC. | $29.64 | 2023 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2024 | Abilify Maintena |
| Allergan, INC. | $22.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.42 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.24 | 2023 | Jornay Pm |
| Lundbeck LLC | $15.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Eilers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.